IP Library Granted Patent US 11,332,749
Granted Patent B2
US 11,332,749 · App. 16/035,286 · Granted May 17, 2022

Real-time reporter systems for monitoring base editing

Inventors: Reuben S. Harris (St. Paul, MN); Daniel James Salamango (Crystal, MN); Amber Renee St. Martin (Maple Grove, MN)
Assignee: Regents of the University of Minnesota
C12N15/635C07K14/43504C07K14/43595C07K16/12C07K16/18C12N9/22C12N9/78C12N15/102C12N15/63C12N15/86C07K14/00C07K2317/24C07K2319/00C07K2319/60C12N2310/20C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,332,749
App. No.
16/035,286
Granted
May 17, 2022
Kind
B2
Abstract

Real-time systems for monitoring base editing in living cells, including base editing by APOBEC-Cas9 fusions, is provided herein.

Claims (22)

1. A nucleic acid comprising:

a first nucleotide sequence encoding a first reporter, wherein the first reporter is inactivated by a revertible mutation within the nucleotide sequence encoding the first reporter, as compared to a reference sequence for the first reporter, wherein the mutation is a T to C point mutation that can be reverted by a base editing complex, and wherein the revertible mutation is about 5 to 20 bp from a Cas protospacer adjacent motif (PAM); and

a second nucleotide sequence encoding a second reporter that is active when it is expressed,

wherein the first and second nucleotide sequences are operably linked to one or more promoters that drive expression of the first and second nucleotide sequences, and

wherein the first and second nucleotide sequences are separated by a nucleotide sequence encoding a self-cleaving peptide.

2. The nucleic acid of claim 1 , wherein the first and second reporters are fluorescent reporter polypeptides.

3. The nucleic acid of claim 1 , wherein the first reporter or the second reporter is a mCherry polypeptide.

4. The nucleic acid of claim 3 , wherein the first reporter is a mCherry polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2, with the proviso that the leucine residue at position 56 of SEQ ID NO:2 is replaced with a serine residue.

5. The nucleic acid of claim 4 , wherein the serine residue is encoded by a TCA codon.

6. The nucleic acid of claim 3 , wherein the second reporter is a mCherry polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.

7. The nucleic acid of claim 1 , wherein the first or second reporter is a green fluorescent protein (GFP) polypeptide.

8. The nucleic acid of claim 7 , wherein the GFP polypeptide is an enhanced GFP (eGFP) polypeptide.

9. The nucleic acid of claim 7 , wherein the first reporter is an eGFP polypeptide comprising the amino acid sequence set forth in SEQ ID NO:4, with the proviso that the leucine residue at position 202 of SEQ ID NO:4 is replaced with a serine residue, the leucine residue at position 138 of SEQ ID NO:4 is replaced by a serine residue, or the tyrosine at position 93 of SEQ ID NO:4 is replaced by a histidine residue.

10. The nucleic acid of claim 9 , wherein the serine residue at position 202 or position 138 is encoded by a TCA codon, or wherein the histidine at position 93 is encoded by a CAC codon.

11. The nucleic acid of claim 7 , wherein the second reporter is an eGFP polypeptide comprising the amino acid sequence set forth in SEQ ID NO:4.

12. The nucleic acid of claim 1 , wherein the revertible mutation is a point mutation that can be reverted by a base editing complex comprising an apolipoprotein B mRNA-editing complex (APOBEC) polypeptide, or a portion thereof.

13. The nucleic acid of claim 12 , wherein the APOBEC polypeptide is rat APOBEC1 or a portion thereof, human APOBEC3A or a portion thereof, human APOBEC3B or a portion thereof, or human APOBEC3H or a portion thereof.

14. The nucleic acid of claim 12 , wherein the APOBEC polypeptide is a human APOBEC3B C-terminal domain.

15. The nucleic acid of claim 12 , wherein the base editing complex comprises an APOBEC polypeptide, a Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)-associated-9 (Cas9) polypeptide, and a uracil DNA glycosylase inhibitor (UGI).

16. A vector comprising the nucleic acid of claim 1 .

17. The nucleic acid of claim 2 , wherein the first and second reporters are selected from the group consisting of Cyan Fluorescent Proteins, GFPs, Yellow Fluorescent Proteins, Orange Fluorescent Proteins, Red Fluorescent Proteins, Far-red fluorescent Proteins, and Switchable Fluorescent Proteins.

18. The nucleic acid of claim 17 , wherein the first and second reporters are selected from the group consisting of AmCyanl, AcGFPl, ZsGreenl, ZsYellowl, mBanana, mOrange, mOrange2, DsRed-Express2, DsRed-Express, tdTomato, DsRed-Monomer, DsRed2, AsRed2, mStrawberry, HcRedl, mRaspberry, E2-Crimson, mPlum, Dendra2, Timer, and PAmCherry.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2020
From: SALAMANGO, DANIEL JAMES; ST. MARTIN, AMBER RENEE
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 053538/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2020
From: HARRIS, REUBEN S.
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 052561/0496 →
CONFIRMATORY LICENSE Recorded Feb 1, 2019
From: UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048228/0825 →
Continuity (2)
Provisional Application 62532064 · Jul 13, 2017
Related Publication 20190017055A1 · Jan 17, 2019